Custom Needle Preparation for Suprachoroidal Steroid Injection (One Year Results)

Study Overview
=================
Brief Summary
-----------------
Suprachoroidal drug delivery is a recent route for managing various ocular conditions. Safety and long term results are still under investigations.

Detailed Description
-----------------
In this study, we aim to analyze the long term results of suprachoroidal injection in treating various retinal diseases to focus on its efficacy, safety and long term ocular effects as ocular hypertension, cataract progression and macular edema resolution.

Official Title
-----------------
One Year Results for Suprachoroidal Triamcinolone Acetonide Injection in Various Retinal Diseases

Conditions
-----------------
Diabetic Macular Edema, Vogt Koyanagi Harada Disease, Retinal Vein Occlusion

Intervention / Treatment
-----------------
* Drug: Suprachoroidal triamcinolone acetonide injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: cases with central macular thickness more than 250 microns measured by optical coherence tomography due to one of the following conditions: Diabetic macular edema Vogt-koyanagi Harada disease Retinal vein occlusion. Exclusion Criteria: other causes of increased macular thickness as age related macular degeneration and myopic choroidal new vascularization. Cases with confirmed diagnosis of glaucoma.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Diabetic macular edema<br>Cases with diabetic macular edema with central macular thickness more than 300 microns measured by optical coherence tomography. | Drug: Suprachoroidal triamcinolone acetonide injection<br>* Pars plana suprachoroidal injection of 4mg//0.1ml triamcinolone acetonide.<br>|
| Active Comparator: Vogt-koyanagi harada<br>Cases with vogt-koyanagi harada and complicated with exudative retinal detachment confirmed by optical coherence tomography. | Drug: Suprachoroidal triamcinolone acetonide injection<br>* Pars plana suprachoroidal injection of 4mg//0.1ml triamcinolone acetonide.<br>|
| Active Comparator: Retinal vein occlusion<br>Cases with retinal vein occlusion and complicated with macular edema confirmed by optical coherence tomography. | Drug: Suprachoroidal triamcinolone acetonide injection<br>* Pars plana suprachoroidal injection of 4mg//0.1ml triamcinolone acetonide.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual acuity | Changes noted in vision after injection measured 8n logMar units by snellen chart. | Baseline and up to one year after injection. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Central macular thickness | Changes noted in central macular thickness after injection measured by optical coherence tomography in microns. | Baseline and up to one year after injection. |